159 related articles for article (PubMed ID: 18949614)
21. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
[TBL] [Abstract][Full Text] [Related]
22. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
Scordo M; Wang TP; Ahn KW; Chen Y; Ahmed S; Awan FT; Beitinjaneh A; Chen A; Chow VA; Dholaria B; Epperla N; Farooq U; Ghosh N; Grover N; Hamad N; Hildebrandt GC; Holmberg L; Hong S; Inwards DJ; Jimenez-Jimenez A; Karmali R; Kenkre VP; Khimani F; Klyuchnikov E; Krem MM; Munshi PN; Nieto Y; Prestidge T; Ramakrishnan Geethakumari P; Rezvani AR; Riedell PA; Seo S; Shah NN; Solh M; Yared JA; Kharfan-Dabaja MA; Herrera A; Hamadani M; Sauter CS
JAMA Oncol; 2021 Jul; 7(7):993-1003. PubMed ID: 33956047
[TBL] [Abstract][Full Text] [Related]
23. Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma.
Joffe E; Rosenberg D; Rozovski U; Perry C; Kirgner I; Trestman S; Gur O; Aviv F; Sarid N; Kolomansky A; Gepstein L; Herishanu Y; Naparstek E
Bone Marrow Transplant; 2018 Jan; 53(1):29-33. PubMed ID: 29035395
[TBL] [Abstract][Full Text] [Related]
24. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
Sellner L; Boumendil A; Finel H; Choquet S; de Rosa G; Falzetti F; Scime R; Kobbe G; Ferrara F; Delmer A; Sayer H; Amorim S; Bouabdallah R; Finke J; Salles G; Yakoub-Agha I; Faber E; Nicolas-Virelizier E; Facchini L; Vallisa D; Zuffa E; Sureda A; Dreger P;
Bone Marrow Transplant; 2016 Feb; 51(2):212-218. PubMed ID: 26569093
[TBL] [Abstract][Full Text] [Related]
25. Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
Seshadri T; Pintilie M; Kuruvilla J; Keating A; Tsang R; Zadeh S; Crump M
Leuk Lymphoma; 2009 Mar; 50(3):380-6. PubMed ID: 19347727
[TBL] [Abstract][Full Text] [Related]
26. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
You B; Salles G; Bachy E; Casasnovas O; Tilly H; Ribrag V; Sebban C; Hénin E; Guitton J; Tod M; Freyer G
Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155
[TBL] [Abstract][Full Text] [Related]
27. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
28. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.
Gutierrez-Delgado F; Holmberg L; Hooper H; Petersdorf S; Press O; Maziarz R; Maloney D; Chauncey T; Appelbaum F; Bensinger W
Bone Marrow Transplant; 2003 Aug; 32(3):279-85. PubMed ID: 12858199
[TBL] [Abstract][Full Text] [Related]
29. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Shimoni A; Avivi I; Rowe JM; Yeshurun M; Levi I; Or R; Patachenko P; Avigdor A; Zwas T; Nagler A
Cancer; 2012 Oct; 118(19):4706-14. PubMed ID: 22252613
[TBL] [Abstract][Full Text] [Related]
30. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
Jantunen E; Kuittinen T; Nousiainen T
Leuk Lymphoma; 2003 Jul; 44(7):1151-8. PubMed ID: 12916867
[TBL] [Abstract][Full Text] [Related]
31. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
Hawkins D; Barnett T; Bensinger W; Gooley T; Sanders J
Med Pediatr Oncol; 2000 May; 34(5):328-37. PubMed ID: 10797354
[TBL] [Abstract][Full Text] [Related]
32. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
[TBL] [Abstract][Full Text] [Related]
33. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
Demirer T; Ayli M; Fen T; Ozcan M; Arat M; Buyukberber S; Arslan O; Gurman G; Akan H; Ilhan O
Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
[TBL] [Abstract][Full Text] [Related]
34. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
[TBL] [Abstract][Full Text] [Related]
36. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
37. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.
Holmberg LA; Demirer T; Rowley S; Buckner CD; Goodman G; Maziarz R; Klarnet J; Zuckerman N; Harrer G; McCloskey R; Gersh R; Goldberg R; Nichols W; Jacobs A; Weiden P; Montgomery P; Rivkin S; Appelbaum FR; Bensinger WI
Bone Marrow Transplant; 1998 Oct; 22(7):651-9. PubMed ID: 9818692
[TBL] [Abstract][Full Text] [Related]
38. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
39. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
40. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity.
Shi Y; Liu P; Zhou S; Yang J; Han X; He X; Zhang C; Gui L; Qin Y; Yang S; Zhao L; Yao J; Jia B; Zhang S; Sun Y; Shi Y
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e423-e429. PubMed ID: 28101911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
